African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy.

Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T, AIDS Clinical Trials Group Study 384 Team, New Work Concept Sheet 273 Team
J Infect Dis. 2010 201 (11): 1703-7

PMID: 20402593 · PMCID: PMC2862090 · DOI:10.1086/652419

Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.

MeSH Terms (15)

Adolescent Adult African Continental Ancestry Group Aged Antiretroviral Therapy, Highly Active DNA, Mitochondrial Female Gene Frequency Humans Male Middle Aged Peripheral Nervous System Diseases Reverse Transcriptase Inhibitors Sequence Analysis, DNA Young Adult

Connections (2)

This publication is referenced by other Labnodes entities: